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Celiac disease (CeD) is a complex T cell-mediated enteropathy induced by gluten.
Although genome-wide association studies have identified numerous genomic regions
associated with CeD, it is difficult to accurately pinpoint which genes in these loci
are most likely to cause CeD. We used four different in silico approaches—Mendelian
randomization inverse variance weighting, COLOC, LD overlap, and DEPICT—to
integrate information gathered from a large transcriptomics dataset. This identified
118 prioritized genes across 50 CeD-associated regions. Co-expression and pathway
analysis of these genes indicated an association with adaptive and innate cytokine
signaling and T cell activation pathways. Fifty-one of these genes are targets of known
drug compounds or likely druggable genes, suggesting that our methods can be used to
pinpoint potential therapeutic targets. In addition, we detected 172 gene combinations
that were affected by our CeD-prioritized genes in trans. Notably, 41 of these
trans-mediated genes appear to be under control of one master regulator, TRAF-type
zinc finger domain containing 1 (TRAFD1), and were found to be involved in interferon
(IFN)γ signaling and MHC I antigen processing/presentation. Finally, we performed in
vitro experiments in a human monocytic cell line that validated the role of TRAFD1 as an
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immune regulator acting in trans. Our strategy confirmed the role of adaptive immunity in
CeD and revealed a genetic link between CeD and IFNγ signaling as well as with MHC I
antigen processing, both major players of immune activation and CeD pathogenesis.
Keywords: celiac disease, gene prioritization, expression quantitative trait locus (eQTL), TRAFD1, trans regulation
INTRODUCTION
Celiac disease (CeD) is an autoimmune disease in which patients
experience severe intestinal inflammation upon ingestion of
gluten peptides. CeD has a large genetic component, with
heritability estimated to be ∼75% (Kuja-Halkola et al., 2016).
The largest CeD-impacting locus is the human leukocyte antigen
(HLA) region, which contributes ∼40% of CeD heritability
(Bevan et al., 1999). While the individual impacts of CeD-
associated genes outside the HLA region are smaller, they jointly
account for an additional 20% of heritability. Previous genome-
wide association studies (GWASs) have identified 42 non-HLA
genomic loci associated with CeD. Yet, identification of these
non-HLA genetic components and an understanding of the
molecular perturbations associated with them are necessary to
understand CeD pathophysiology.
Understanding the biological mechanisms of non-HLA CeD
loci is difficult: only three of these loci point to single-
nucleotide polymorphisms (SNPs) located in protein-coding
regions (Trynka et al., 2011). The other CeD-risk loci cannot
be explained by missense mutations, making it necessary to
look at other biological mechanisms such as gene expression
to explain their role in CeD pathogenicity. Several studies
have been performed to integrate expression quantitative trait
loci (eQTLs) with CeD GWAS associations (Dubois et al.,
2010; Kumar et al., 2015; Ricaño-Ponce et al., 2016), and
several candidate genes, including UBASH3A, CD274, SH2B3,
and STAT4 (Zhernakova et al., 2011), have been identified,
implicating T cell receptor, nuclear factor (NF)κB, and interferon
(IFN) signaling pathways as biological pathways associated with
CeD pathology. Unfortunately, these eQTL studies had limited
sample sizes, which reduced their power to identify cis- and
(especially) trans-eQTLs. Furthermore, previous attempts to
integrate eQTLs have mostly annotated genomic loci based on
cataloged eQTLs without testing the causality of the genes in the
onset or exacerbation of CeD (Ricaño-Ponce et al., 2016; Jonkers
and Wijmenga, 2017; Fernandez-Jimenez and Bilbao, 2019).
Gene expression and GWAS data can also be integrated
using methodologies that identify shared mechanisms between
diseases. Thesemethods can be roughly divided into three classes:
variant colocalization methods, causal inference methods, and
co-expression methods. Colocalization methods consider the
GWAS and eQTL summary statistics at a locus jointly and
probabilistically test if the two signals are likely to be generated
by the same causal variant (Giambartolomei et al., 2014). Causal
inference methods test if there is a causal relationship between
expression changes and the disease using genetic associations
to remove any confounders (Burgess et al., 2013; van der Graaf
et al., 2020). Finally, co-expression methods do not use eQTL
information, but rather test if there is significant co-expression
between the genes that surround the GWAS locus (Pers et al.,
2015). Unfortunately, there is no current “gold standard” method
for finding the causal gene behind a GWAS hit, as all the methods
discussed here are subject to their respective assumptions,
drawbacks, and caveats. However, it is worthwhile to use all these
methods in parallel to find the most likely causal genes for CeD.
Here, we systematically applied four prioritization methods
to the latest meta-analysis for CeD that we have performed
previously (Ricaño-Ponce et al., 2020) and coupled them with
eQTL results from the Biobank Integrative Omics Study (BIOS)
cohort (Zhernakova et al., 2017), one of the largest cohorts
for which there is genotype and RNA sequencing (RNA-seq)
expression data of peripheral blood mononuclear cells. We
focused on 58 CeD-associated loci (p < 5 × 10−6) outside the
HLA region. Our approach prioritized 118 genes in 50 loci and
identified one gene, TRAF-type zinc finger domain containing
1 (TRAFD1), as a master regulator of trans-effects. We then
experimentally validated the role of TRAFD1-mediated genes
using a TRAFD1 knockdown through RNA-seq in a disease-
relevant cell type. Our study yields novel insights into the genetics
of CeD and is proof-of-concept for a systematic approach that
can be applied to other complex diseases. A schematic overview
of our study is shown in Supplementary Figure 1A.
NOMENCLATURE
Underlined words are definitions that have been explained in the
preceding lines.
eQTL, expression quantitative trait locus, a location on
the genome that is statistically associated with changes in
gene expression.
cis-eQTL, an eQTL located in the same locus of the gene that
is being interrogated (within 1.5 Mb from gene transcript start
or end).
trans-eQTL, an eQTL that is not physically close to the gene that
is being interrogated (>1.5 Mb from transcript start/end or on a
different chromosome).
cis-eQTL gene, a gene that is associated with a change in
expression as a consequence of a cis-eQTL.
trans-eQTL gene, a gene that is associated with a change in
expression as a consequence of a trans-eQTL.
CeD, celiac disease
CeD-associated region, a genomic region that is associated
with CeD based on results from genome-wide association studies
on CeD.
Prioritized gene, a gene prioritized as being potentially
causal for CeD according to the four statistical
methods depicted in Supplementary Figures 1B,C.
In this study, prioritized genes are always within the
Frontiers in Genetics | www.frontiersin.org 2 January 2021 | Volume 11 | Article 562434
van der Graaf et al. TRAFD1 Is Trans-Regulator in CeD
CeD-associated regions.
Mediating cis gene, a prioritized gene that is statistically
responsible for the change in expression of a trans-eQTL
gene. Of note, while the trans-eQTL is located in the same
CeD-associated region of the mediating cis-gene, the mediated
trans-gene is not.
Mediated trans gene, a gene located outside
CeD-associated regions that is statistically mediated by
a mediating cis gene located in the same region of the
corresponding trans-eQTL.
MATERIALS AND METHODS
Genotypes for Expression Quantitative
Trait Loci Analysis
We used the BIOS cohort (Zhernakova et al., 2017) to map
eQTLs in 3,746 individuals of European ancestry. The BIOS
cohort is a collection of six cohorts: the Cohort on Diabetes
and Atherosclerosis Maastricht (van Greevenbroek et al., 2011),
the Leiden Longevity Study (Deelen et al., 2016), Lifelines
DEEP (Tigchelaar et al., 2015), the Netherlands Twin Registry
(Lin et al., 2016), the Prospective ALS Study Netherlands
(Huisman et al., 2011), and the Rotterdam Study (Hofman et al.,
2015). As described in Võsa et al. (2018), each cohort was
genotyped separately using different arrays, and genotypes were
subsequently imputed to the Haplotype Reference Consortium
panel (HRC v1.0) on the Michigan imputation server (Das et al.,
2016).
While genotyping data were generated and imputed
independently of this study (Võsa et al., 2018), here we applied
additional filters at the marker and sample level. Specifically,
we considered only biallelic SNPs with a minor allele frequency
(MAF) >0.01, a Hardy–Weinberg test p > 10−6, and an
imputation quality RSQR > 0.8. We also removed related
individuals using a genetic relationship matrix (GRM) created
with PLINK 1.9 (Chang et al., 2015). Pairs of individuals with
a GRM value >0.1 were considered related, and one individual
was removed from each of these pairs. Furthermore, population
outliers were identified using a principal component analysis
on the GRM, and individuals who were more than 3 standard
deviations from the means of principal component 1 or 2
were removed.
Expression Quantification and Expression
Quantitative Trait Loci Analysis
We used preprocessed RNA-seq data from a previous study
(Zhernakova et al., 2017; Võsa et al., 2018). After matching the
RNA-seq data with the genotyping data filtered described above,
3,503 individuals, 19,960 transcripts, and 7,838,327 autosomal
SNPs remained for analyses. We performed genome-wide eQTL
mapping for the transcripts using PLINK 1.9 (Chang et al., 2015)
with the –assoc command.We defined cis-eQTL variants as those
located within ± 1.5Mb of the transcript and trans-eQTLs as
variants located outside these boundaries. Of note, we opted for
this larger window for defining cis-eQTLs (usually is ± 500Kb)
so that eQTL associations would fully overlap the associated
CeD GWAS peak even when a gene is on the edge of the CeD-
associated region (chosen to be 1Mb). To select variants that
could explain the cis-eQTL signal of a gene, we usedGCTA-COJO
(Yang et al., 2011) v1.26. For this analysis, we required selected
variants to reach a p-value threshold of 5× 10−6 and included the
BIOS cohort genotypes as LD reference. This identified 707 genes
with at least one eQTL reaching this threshold, 357 of which had
more than one conditionally independent eQTL variant.
Celiac Disease Summary Statistics
Associated Regions and Candidate Genes
We used summary statistics from a CeD GWAS meta-analysis
of 12,948 cases and 14,826 controls that analyzed 127,855
variants identified using the ImmunoChip array (Ricaño-Ponce
et al., 2020). SNP positions were lifted over to human genome
build 37 using the UCSC liftover tool. We first identified lead
associated variants in the CeD meta-analysis by performing p-
value clumping: we used PLINK 1.9 (Chang et al., 2015) to
select variants at a p-value threshold of 5 × 10−6 and pruned
variants in LD with these selected variants using standard PLINK
settings (r2 > 0.5, utilizing 1,000 Genomes European sample
LD patterns and ± 250Kb window) (Auton et al., 2015; Chang
et al., 2015). We removed variants in an extended HLA region
(chromosome 6, 25–37Mb) due to the complex long-range LD
structure in this region and because we aim to understand the
function of the non-HLA genetic component of CeD. We looked
for candidate genes around the clumped variants as follows.
First, we considered all genomic regions around (±1Mb) every
clumped variant to also capture variants in long-range LD that
are outside the standard ±500Kb window (Yang et al., 2012).
We then joined all overlapping CeD-associated regions together
and looked for gene transcripts that partly or fully overlapped
with the associated regions. This approach identified 58 CeD-
associated regions and 1,235 candidate genes that are potentially
causal for CeD.
Gene Prioritization Using Mendelian
Randomization Inverse Variance
Weighting, COLOC, LD Overlap, and
DEPICT
We prioritized CeD-associated genes using three eQTL-based
methods—MR-IVW (Burgess and Thompson, 2017), COLOC
(Giambartolomei et al., 2014), and LD overlap—and one co-
regulation-based method, DEPICT (Pers et al., 2015). For the
MR-IVW method, we used the independent variants identified
by GCTA-COJO as instrumental variables (Yang et al., 2012;
Burgess et al., 2013) to test causal relationships between changes
in gene expression and CeD, as we have demonstrated that
this procedure is preferred over p-value clumping (van der
Graaf et al., 2020). MR-IVW was only performed when there
were three or more independent eQTLs available (164 genes).
A gene was significant for the MR-IVW test if the causal
estimates passed a Bonferroni threshold p-value of 3.1 × 10−4.
Heterogeneity of causal estimates was evaluated using weighted
median MR analysis and Cochran’s Q-test (Bowden et al., 2018).
For the COLOC method, we used the “coloc” v3 R package
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and considered a gene significant for the COLOC analysis if the
posterior probability of shared variants (H4) was larger than 0.9.
For the LD overlap method, a gene was considered significant
if there was high LD (r2 > 0.8) between the top independent
eQTL and the top CeD variant in the region. Finally, we applied
DEPICT (Pers et al., 2015) to the clumped CeD GWAS variants
described in Celiac Disease Summary Statistics Associated Regions
and Candidate Genes. Genes identified by the DEPICT analysis
were considered significant if a false discovery rate (FDR) <0.05
was found with DEPICT’s own permutation measure.
We scored each gene in the CeD-associated loci by
considering each of the four prioritization methods. A gene
was prioritized as “potentially causal” in CeD pathology when
one of the four methods was significant (one line of evidence).
If multiple lines of evidence were significant, the gene was
prioritized more highly than when only a single line of evidence
was available.
To explore how the prioritized genes affect CeD risk, we
gave each gene an effect direction based on the effect direction
of the top variants in the eQTL and the CeD GWAS. We
assigned positive (“+”) when increased expression increases CeD
risk, negative (“–”) when increased expression decreases CeD
risk and “?” when it was not clear from our results how the
expression affects CeD risk. To assign these directions, we used
the following procedure:
1 If there was a concordant effect that was significant in the top
variants of both the eQTLs and the GWASs, the direction of
the concordant effect was chosen.
2 If there was a concordant effect but no significance of the
SNP in one of the datasets, we could not be sure of an
effect direction, and a question mark was chosen. The only
exception to this was if the MR-IVW was significant, in which
instance we chose the direction of the MR-IVW effect as
effect direction.
3 If there was a discordant effect between the top SNPs and
both were significant in both datasets, a question mark was
chosen. The only exception to this was when theMR-IVWwas
significant, the MR-IVW effect was chosen.
4 If the effect between the eQTL top SNP and CeD top SNP was
not in the same direction and only the eQTL top SNPs were
genome-wide significant, the eQTL direction was chosen.
5 If the effect between the eQTL top SNP and CeD top SNP was
not in the same direction and only the GWAS top SNPs were
genome-wide significant, the GWAS direction was chosen.
6 Otherwise, a question mark was chosen.
Co-regulation Clustering
The genes that have been prioritized may have some shared
function in CeD pathology. To identify possible shared pathways,
we performed co-regulation clustering analysis based on 1,588
normalized expression co-regulation principal components
identified from RNA-seq information across multiple human
tissues by Deelen et al. (2019). We performed pairwise Pearson
correlation of our prioritized genes with these 1,588 principal
components and derived a correlation Z score for each prioritized
gene pair. We then performed hierarchical clustering of this Z
score matrix using Ward distances and identified four clusters
from the resulting dendrogram.
Trans-eQTL and Mediation Analysis
A total of 238 autosomal genes that were not located in, but
were associated with, a significant trans-eQTL variant (p <
5 × 10−8) in the CeD-associated regions were identified and
used as potential targets for mediation by our associated genes
in the CeD-associated loci (86 potential cis mediating genes).
We first selected trans-eQTL genes that were co-expressed
(Pearson r > 0.1, 197 gene combinations) with prioritized genes,
then performed mediation analysis by running the trans-eQTL
association again using the expression of the cis-eQTL gene as a
covariate. We defined a trans-mediated gene if, after mediation
analysis, the change (increase or decrease) in the effect size
of the top trans-eQTL variant was significant according to the
statistical test described in Freedman and Schatzkin (Freedman
and Schatzkin, 1992). For this analysis, we used a Bonferroni-
adjusted p-value of 3.0× 10−4.
Cell Type Proportion and SH2B3
Expression Mediation Analysis
To assess if the cis-eQTL effect of TRAFD1 was not a proxy
for cell type composition, we performed mediation analyses in a
fashion similar to the trans-mediation analysis above using cell
proportions measured in a subset of individuals in the BIOS
cohort. To ensure that there was no residual effect of SH2B3
expression on the mediating effect of TRAFD1, we corrected the
original TRAFD1 expression levels for the expression levels of
SH2B3, leaving TRAFD1 expression independent of SH2B3, and
reran the mediation analysis.
Literature Review
We performed a REACTOME pathway (Chen et al., 2013)
analysis to determine the potential function of the prioritized
genes. This was complemented with a literature search (research
and review papers) in Pubmed. For the coding and non-
coding genes for which no studies were found, Genecards
(www.genecards.org) and Gene Network v2.0 datasets (Deelen
et al., 2019) were used, respectively. Information regarding the
potential druggability of the prioritized genes was obtained from
DrugBank (Wishart et al., 2018), the pharmacogenetics database
(Whirl-Carrillo et al., 2012), and a previous study that cataloged
the druggability of genes (Finan et al., 2017).
THP-1 Experiments
Culturing of the THP-1 Cell Line
The cell line THP-1 (Sigma Aldrich, ECACC 88081201) was
cultured in RPMI 1640 with L-glutamine and 25mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Gibco,
catalog 52400-025) and supplemented with 10% fetal bovine
serum (Gibco, catalog 10270) and 1% penicillin/streptomycin
(Lonza, catalog DE17602E). The cells were passed twice per
week at a density lower than 0.5 × 106 cells/ml in a humidified
incubator at 5% CO2, 37
◦C.
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siRNA Treatment of THP-1 Culture
THP-1 cells were plated at 0.6 × 106 cells/ml and transfected
with 25 nM siRNA using Lipofectamine RNAimax transfection
reagent (Invitrogen, catalog 13788), according to the
manufacturer’s protocol. Cells were treated with an siRNA
to target TRAFD1 (Qiagen catalog 1027416, sequence CCC
AGCCGACCCATTAACAAT) [Knockdown (KD)], and cells
treated with transfection mix without siRNA [wild type (WT)]
or non-targeting control siRNA [scrambled (SCR)] (Qiagen
catalog SI03650318, sequence undisclosed by company) were
included as controls. All the treatments were performed in
triplicate. Seventy-two hours after transfection, a small aliquot
of cells was stained for Trypan Blue exclusion to determine
cell viability and proliferation. The cells were stimulated with
either lipopolysaccharide (LPS) (10 ng/ml) from Escherichia coli
(Sigma catalog 026:B6) or media alone (unstimulated) for 4 h.
Subsequently, the cells were centrifuged, and the cell pellets were
suspended in lysis buffer and stored at −80◦C until used for
RNA and protein isolation.
qPCR of THP-1 Culture
The total RNA from THP-1 cells was extracted with the
mirVanaTM miRNA isolation kit (AMBION, catalog AM1561)
and subsequently converted to cDNA using the RevertAid H
Minus First Strand cDNA Synthesis Kit (Thermo Scientific,
catalog K1631). qPCR was done using the Syber green mix
(Bio-Rad, catalog 172-5124) and run in a QuantStudio 7 Flex
Real-Time system (Applied Biosystems, catalog 448598). Primer
sequences to determine KD levels of TRAFD1 were 5′ GCTGTT
AAAGAAGCATGAGGAGAC and 3′ TTGCCACATAGTTCC
GTCCG. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as endogenous qPCR control with primers 5′ ATG
GGGAAGGTGAAGGTCG and 3′ GGGGTCATTGATGGCAA
CAATA. Relative expression values of TRAFD1 were normalized
to the endogenous control GAPDH and calculated using the
11CT method, then given as a percentage relative to SCR
expression levels.
Western Blot THP-1 Culture
Cell pellets from THP-1 cells were suspended on ice-cold lysis
buffer [phosphate buffer saline (PBS) containing 2% sodium
dodecyl sulfate (SDS) and complete protease inhibitor cocktail
(Roche, catalog 11697498001)]. Protein concentration of cell
extracts was determined using the bicinchoninic acid (BCA)
protein kit (Pierce, catalog 23225). Proteins were separated on
10% SDS-polyacrylamide electrophoresis gel and transferred to
a nitrocellulose membrane. After 1 h of blocking with 5% fat-
free milk in Tris-Tween-Buffer-Saline, the membranes were
probed for 1 h at room temperature with mouse monoclonal
TRAFD1 antibody 1:1,000 (Invitrogen, catalog 8E6E7) or
mouse monoclonal anti-actin antibody 1:5,000 (MP Biomedicals,
catalog 08691001), followed by incubation with goat anti-
mouse horseradish peroxidase-conjugated secondary antibodies
1:10,000 (Jackson ImmunoResearch, catalog 115-035-003). After
three 10-min washes, the bands were detected by Lumi-Light
Western blot (WB) substrate (Roche, catalog 12015200001) in a
Chemidoc MP imaging system (Bio-Rad) and quantified using
Image LabTM software (Bio-Rad). The band intensity of TRAFD1
was normalized to actin, and the TRAFD1 SCR control level was
set as 100%.
Statistical Analysis for in vitro Experiments in THP-1
The statistical analyses of proliferation, qPCR, and WB were
performed using Prism 5 software (GraphPad Software, Inc.).
Results are presented as mean ± SEM from a representative
experiment. Statistical differences were evaluated using a one-
tailed t-test.
RNA Sequencing in THP-1 Cells
RNA from THP-1 cells was extracted with the mirVanaTM
miRNA isolation kit (AMBION, catalog AM1561). Prior to
library preparation, extracted RNAwas analyzed on the Experion
Stdsend RNA analysis kit (Bio-Rad, catalog 7007105). Here, 1
µg of total RNA was used as input for library preparation using
the quant seq 3′ kit (Lexogen, catalog 015.96), according to the
manufacturer’s protocol. Each RNA library was sequenced on the
Nextseq500 (Illumina). Low-quality reads, adaptors, and poly-A
tail reads were removed from FASTQ files. The QC-ed FASTQ
files were then aligned to the human_g1k_v37 Ensembl Release
75 reference genome using HISAT default settings Kim D. et al.,
2015) and sorted using SAMtools (Li et al., 2009). Gene-level
quantification was performed by the featurecounts function of
the RSubread R package v1.6.2 (Liao et al., 2019). A modified
Ensembl version 75 gtf file mapping only to the last 5′ 500 bps per
gene was used as gene-annotation database to prevent counting
of reads mapping to intra-genic A-repeats. Gene-level differential
expression analysis between conditions was performed using the
DESeq2 R package (Anders and Huber, 2010) after removing
genes with zero counts. Differentially expressed genes (DEGs)
were defined as genes presenting an absolute log2 fold change
(|log2 FC|) >1 and an FDR ≤0.01 across treatment (WT vs.
SCR or KD unstimulated cells). To identify the genes responding
to LPS stimulation, the DEGs between unstimulated samples
and their respective stimulated samples were determined. Venn
diagrams were used to depict the relationships among these
genes. REACTOME pathway analyses were performed to identify
biological processes and pathways enriched in different sets of
DEGs using the Enrichr API. Enrichments were considered
significant if they were below a 0.05 FDR threshold defined by
the Enrichr API (Chen et al., 2013). Raw data and count matrix
are available under Gene Expression Omnibus (GEO) accession
number GSE146284.
Gene Set Permutation Analysis
It can be difficult to determine if a set of genes is “on average”
more or less differentially expressed due to co-expression
between the genes within the set. To mitigate this, we performed
a permutation test that considers the median absolute T statistic
calculated by DESeq2 (Anders and Huber, 2010). This allowed
us to compare the expected differential expression of an arbitrary
set of genes when exposed to a non-targeting siRNA with that
of the observed differential expression of a siRNA targeting
TRAFD1. We compare the median differential expression in the
WT-SCR comparison, with the observed differential expression
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of the same set of genes in the SCR-KD comparison. This will still
incorporate the co-expression structure of the data. To do this, we
randomly selected a same-sized set of genes 1,000,000 times in
each relevant experiment (WT-SCR or SCR-KD) and determined
the observed median absolute T statistic. We calculated a ratio of
how often the permuted value is higher than the observed value.
For example, the observations can be that 1% of permuted gene
sets are more differentially expressed in theWT-SCR experiment,
while only 0.01% of permuted gene sets are more differentially
expressed in the SCR-KD experiment. Finally, we divide these
values by one another (percentage SCR-KD)/(percentage WT-
SCR), to calculate a fold change in differential expression. In
the example given above, this indicates that the KD is 100 times
(0.01/1= 100) more differentially expressed than expected.
Available RNA Sequencing Datasets
Four RNA-seq datasets available to us were included to study the
pattern of expression of prioritized genes. A brief description of
each dataset is provided below.
(i) Whole Biopsy Samples Duodenal biopsies were obtained
from 11 individuals (n = 6 CeD patients and n = 5 controls)
who underwent upper gastrointestinal endoscopy (previously
described) (Zorro et al., 2020). Data can be found under
accession number GSE146190.
(ii) Intraepithelial Cytotoxic T Lymphocytes CD8+ T cell
receptor (TCR)αβ Intra-Epithelial Cytotoxic CD8+ T
Lymphocytes (IE-CTLs) cell lines were isolated from
intestinal biopsies and expanded, as described previously
(Jabri et al., 2000). Stimulations [interleukin (IL)-15, IFNβ, or
IL21] and DEG analysis were described by Zorro et al. (2020).
Data can be found under accession number GSE126409.
(iii) Gluten-Specific T Cells
Stimulations with anti-CD3 and anti-CD28 (n = 22 samples
per condition were done in six-well-plates coated overnight
with anti-CD3 (2.5µg/ml; Biolegend, San Diego, CA, USA)
and anti-CD28 (2.5µg/ml; Biolegend, San Diego, CA, USA)
or PBS (negative control) for 0, 10, 30, and 180min. At
each time point, cells were harvested for RNA isolation. RNA
was extracted with the mirVana RNA isolation kit (Ambion,
Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The quantity and quality of RNA
were determined by Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). The sequencing libraries were prepared
from 1µg of total RNA using the TruSeq Stranded Total RNA
with Ribo-Zero Globin kit (Illumina, San Diego, CA, USA)
according to the manufacturer’s instructions. Sequencing was
done with the Illumina HiSeq2500 (Illumina, San Diego,
CA, USA).
Before alignment, the reverse complement of the fastQ
sequences was taken using the FASTX-Toolkit (http://
hannonlab.cshl.edu/fastx_toolkit). The alignment was done
using Hisat2 version 2.0.4 against the forward strand with
default alignment parameters (Kim D. et al., 2015). The
reference genome index was made using hisat2-build indexer
and the 1,000 genomes reference genome version GRCh37
v75, with default parameters. For the samples that had paired
end data, only the firstmate file was used for alignment. Reads
mapping to multiple positions were removed.
The genes were quantified using HTSeq (Love et al.,
2014) version 0.6.1.p1, with options -m union, -t exon, –
stranded yes, and other options on default. DE effects were
quantified using the R package DEseq2 (version 1.26.0) (Love
et al., 2014) and filtered on having an absolute log2 fold
change (|log2 FC|) of at least 1 and an FDR <0.05. Data
are available under accession number GSE146441 (Bakker
et al., submitted).
(iv) Caco-2 Cells
Stimulation of the Caco-2 cell line with 60 ng/ml IFNγ
(PeproTech) and DEG analysis were previously described
(Zorro Manrique, 2020). Data can be found under accession
number GSE146893.
RESULTS
Gene Prioritization Identifies 118 Likely
Causal Celiac Disease Genes
To identify genes that most likely play a role in CeD (prioritized
genes), we combined our recently published genome-wide
association meta-analysis (Ricaño-Ponce et al., 2020) with (1)
eQTLs derived from whole-blood transcriptomes of 3,503 Dutch
individuals (Zhernakova et al., 2017) and (2) a co-regulation
matrix derived from expression data in multiple different tissues
and 77,000 gene expression samples (Pers et al., 2015). We
selected 1,258 genes that were within 1Mb of the 58 CeD-
associated non-HLA variant regions (p < 5 × 10−6) (see
Methods) and prioritized the genes that are the most likely
related to CeD using four different gene prioritization methods:
MR-IVW (Burgess et al., 2013), COLOC (Giambartolomei
et al., 2014), LD overlap, and DEPICT (Pers et al., 2015)
(Supplementary Figures 1B,C, Supplementary Table 1).
The first three methods use summary statistics of eQTLs
and the CeD GWAS. MR-IVW is a test that assesses the causal
relationship between a gene expression and the disease using
the gene eQTLs as instruments (Burgess et al., 2013; van der
Graaf et al., 2020) (see Methods). MR-IVW was applied to 162
genes, for which three or more independent cis-eQTL variant
(at p < 5 × 10−6) were identified (see Methods) (Yang et al.,
2012) and shown to be consistent after heterogeneity correction
(Supplementary Table 2) (see Methods). COLOC is a variant
colocalization test that assesses if there is a shared causal variant
in the locus using all the variants in locus a instruments
(Giambartolomei et al., 2014) (see Methods). LD overlap is an
annotation approach that tests if the most associated variants in
a GWAS locus are in strong LD with an eQTL (see Methods).
DEPICT was the fourth method we used to prioritize genes.
DEPICT is a gene prioritization method based on co-regulation
in expression datasets across multiple different tissues. DEPICT
identifies enrichment for co-regulated genes from genes in a
GWAS locus. In contrast to the other methods, DEPICT assessed
the potential role of all 1,258 genes independently of the presence
of an eQTL.
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In total, 118 out of the 1,258 assessed genes were prioritized
by at least one of the four methods. Of these 118 genes,
28 had two lines of evidence, seven genes (CD226, NCF2,
TRAFD1, HM13, COLCA1, CTSH, UBASH3A) had three lines of
evidence, and one gene (CSK) was supported by all four methods
(Supplementary Table 1, Figure 1A). Overall, we identified
potentially causal genes in 50 out of 58 CeD-associated regions.
The four different gene prioritization methods complement
each other in different ways. DEPICT prioritized the most genes:
66 in total but also had the highest proportion of 38 of them
uniquely prioritized (38/66, 58% unique). One reason for this
is that DEPICT is based on co-expression, not on eQTLs, and
thus more genes could be tested. Indeed, 16 genes prioritized
by DEPICT do not have a significant eQTL. Overall, the highest
concordance between prioritization methods was found between
COLOC and LD overlap (30 and 26% unique genes, respectively),
while MR-IVW uniquely prioritized a relatively large proportion
of genes (9/20, 45% unique). Thus, each method prioritizes genes
somewhat similarly but adds a unique set of genes based on the
peculiarities and assumptions of the specific method.
Interestingly, 26 of the 118 prioritized genes are targeted by an
approved drug or a drug in development according to DrugBank
and Finan et al. (2017) (Figure 1A, Supplementary Table 3)
and therefore could lead to therapeutic interventions in CeD.
For example, drugs such as natalizumab and basiliximab that
target the proteins encoded by ITGA4 and IL21R, respectively,
are currently approved or under study for the treatment of
immune-mediated diseases including rheumatoid arthritis (Chiu
and Ritchlin, 2017), Crohn’s disease (Rutgeerts et al., 2009),
and multiple sclerosis (Baldassari and Rose, 2017) or as an
immune suppressor to avoid kidney transplant rejection. An
additional 25 genes encode proteins that are similar to proteins
targeted by already approved drugs following Finan et al. (2017)
(Supplementary Table 3).
Through a systematic literature review, we found that these
118 genes may participate in general biological processes
such as cell adhesion and proliferation (C1orf106 and FASLG,
respectively) (Figure 1B, Supplementary Table 4) as well as
immune-associated processes. For instance, genes such as
THEMIS, IL2, CD28, CTLA4, and UBASH3A are involved in T
cell activation and co-stimulation. Other genes including CCR1,
CC2, and IL21 participate in inflammation by activating and
recruiting monocytes, dendritic cells, neutrophils, and B cells
(Esche et al., 2005). Interestingly, we also find genes that encode
for transcription factors (e.g., IRF4 and ETS1) that are essential
for the differentiation of T helper 1 (Th1) cells (Grenningloh
et al., 2005; Mahnke et al., 2016), the key players in the
pathogenesis of CeD.
Co-regulation Patterns of cis-Expression
Quantitative Trait Loci-Prioritized Loci
Reveals Four Functional Clusters
We sought to further understand the biological role of
these 118 genes using a guilt-by-association co-regulation
approach to identify clusters of shared molecular function (see
Methods). We identified four different clusters based on their
expression co-regulation with 1,588 principal components that
were identified from the co-expression of 31,499 RNA-seq
samples across multiple tissues (Deelen et al., 2019) (Figure 2A,
Supplementary Table 5).
In three out of four co-regulation clusters, we find
shared immune function. For instance, STAT1, CD274, and
IL12A are in the same cluster and are all involved in
IFNγ and IL-6 signaling, later referred to as; we refer to
it as the cluster enriched for IFNγ signaling (Figure 2B,
Supplementary Table 6). In another cluster, we find genes
involved in T cell receptor-mediated activation and CD28 co-
stimulation (e.g., CD28, CTLA4, and ICOS), we refer to this
cluster as the cluster enriched for TCR activation (Figure 2B).
In the third cluster, we find genes involved in cytokine
and chemokine signaling genes, namely, CCR1, CCR2, CCR3,
IL2EA, IL21, and IL18R1; the cluster enriched for chemokine
receptor binding (Figure 2B, Supplementary Table 6). The
biological processes found in these clusters are essential for
the activation and function of both the innate and adaptive
immune systems.
The enrichments found for these clusters do not fully
define the biological function of these clusters. However, this
co-regulation clustering approach has the benefit that it can
assign putative function to otherwise unknown genes. For
example, long non-coding RNA (lncRNA) genes are usually
hard to assign function to, even though they represent ∼10%
of our prioritized genes. Based on their cluster membership
and the principle of guilt-by-association to assign function to
unknown genes, most of the prioritized lncRNAs are likely
to be involved in cytokine/chemokine signaling (Figures 2A,B,
Supplementary Table 6).
Mediation Analysis Uncovers TRAFD1 as a
Major Trans-eQTL Regulator
To further understand the potential regulatory function of the
118 prioritized genes, we identified downstream regulatory
effects by performing a trans-mediation analysis using a two-
step approach (see Methods) (Supplementary Figure 2A).
We first considered all genes with a trans-eQTL (p < 5
× 10−8) located in any of the 58 CeD-associated regions,
then performed a mediation analysis by reassessing the
trans-eQTL effect after adjusting the expression levels
for the expression of the prioritized gene(s) in the
same locus.
Of the 497 possible prioritized gene–trans-eQTL gene
combinations, we found 172 that exhibited significant mediation
effects. These combinations map to 13 associated regions
and represent 21 unique mediating cis-eQTL genes and 79
unique mediated trans-eQTL genes (Supplementary Table 7).
Among all the associated regions, the CeD-associated region
on chromosome 12 contained the largest number of both
cis-mediating genes (N = 5) and trans-mediated genes (N = 60).
In this region, TRAFD1 (which had three lines of evidence in our
prioritization analysis described in Gene Prioritization Identifies
118 Likely Causal Celiac Disease Genes) mediated more trans
genes (N = 41) than all of the other regional cis-regulators
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FIGURE 1 | Celiac disease (CeD) prioritized genes and their proposed function and cell type. (A) A chromosome ideogram depicting the location of each prioritized
gene identified in a CeD-associated genome-wide association study (GWAS) locus. Loci are marked with red bars. Genes depicted by a square are the target of an
approved drug or a drug in development. All other genes are depicted by a circle. Each circle or square is colored according to the lines of evidence (see Methods)
supporting its causal role. (B) Functions and cell types highlighted by the prioritized genes, according to our literature review (see Methods) (n = 118 genes; for 37
genes, neither a function nor a specific cell type on which the gene may operate could be specified). All genes contributing to a specific function are listed under the
subheading and colored according to the change that leads to increased CeD risk: increased expression (red), decreased expression (blue), or undefined (black). The
symbols + or – denote if a biological process is thought to be induced or repressed by the gene, respectively, according to literature.
and also had the highest mediation impact (average Z-score
difference in effect size between mediated and unmediated
analysis = 2.79) (see Methods) (Supplementary Table 7,
Supplementary Figures 2B,C). Of note, the top eQTL variant of
TRAFD1 is a missense variant in the nearby gene SH2B3. This
SNP has previously been described to be a trans-eQTL in blood
by Westra et al. (2013). In a larger trans-eQTL analysis, Võsa
et al. (2018) found 502 significant trans genes. Furthermore,
this missense variant has also been associated with a number
of complex traits, including blood cell types and platelets, and
autoimmune diseases (Astle et al., 2016; Westra et al., 2018).
However, our TRAFD1 results are not confounded by cell type,
as cell type composition did not affect the eQTL association
of TRAFD1 in our cohort (p > 0.044 for 24 different cell type
traits) (see Methods) (Supplementary Table 8). To ensure that
the mediated trans genes of TRAFD1 were not also mediated
by SH2B3, we corrected TRAFD1 expression levels for SH2B3
expression levels and reran the mediation analysis. Here, we
found that the mediating effect of TRAFD1 was still significant
for all 41 trans-mediated genes and that the median Z-score
difference between mediated and unmediated was higher than
that of SH2B3, although it was slightly attenuated compared
to the original TRAFD1 signal (Supplementary Table 9,
Supplementary Figure 2C). Based on these results, we conclude
that TRAFD1 mediates 41 other genes in trans independently of
SH2B3 expression (Figure 3A).
Strikingly, three of the TRAFD1 trans-mediated genes—
STAT1, CD274, and PDCD1LG2—are also prioritized cis genes
in their respective loci (Figure 3A). These results suggest that the
trans-mediated TRAFD1 effects may have an additional additive
effect in these CeD-associated loci.
TRAFD1 is a poorly characterized gene that has been
suggested to act as a negative regulator of the NFκB pathway
(Sanada et al., 2008). To further elucidate the biological processes
in which the 41 TRAFD1 trans-mediated genes could be involved,
we performed a REACTOME 2016 gene set enrichment analysis
(Supplementary Table 10). Here, we found that IFNγ signaling,
cytokine signaling, and major histocompatibility complex class I
(MHC I) antigen processing/presentation are enriched pathways,
which points to a role for TRAFD1 and TRAFD1 trans-mediated
genes in antigen presentation and immune response (Figure 3B).
Many of the TRAFD1 trans-mediated genes, including
GBP1/2/4/5/6, TAP1, PSME2, PSMB10, UBE2L6, and FBXO6,
seem involved in the processing of antigens via phagocytosis,
ubiquitination, and proteasomal processing (Meunier and
Broz, 2016; Øynebråten I., 2020). However, some of the
trans-mediated genes may also be involved in IgG-dependent
class II MHC antigen presentation, including FCGR1A, and
TRIM21 (Lu et al., 2018). This confirms that IFNγ signaling,
cytokine signaling, and antigen processing and presentation are
associated with CeD through genetics, independently of the HLA
locus (Kumar et al., 2015).
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FIGURE 2 | Co-expression pattern of cis-eQTL prioritized genes. (A) Heatmap showing the Spearman correlations between gene expression patterns of each
prioritized gene. Blue squares indicate a negative correlation. Red squares indicate a positive correlation. Both are shaded on a gradient scale according to the Z
score of the correlation. A dendrogram computed with Ward distances between the correlations is shown on top of the heatmap. Branches of the dendrogram are
colored differently to mark separate clusters. (B) Results of the REACTOME gene set enrichment analysis of the genes belonging to each of the clusters identified in
(A). Color key denotes the significance (-log 10 multiple testing adjusted p-value) of each biological pathway.
siRNA Knockdown of TRAFD1 Confirms
Trans-Mediated Genes Are Differentially
Expressed
We performed a siRNAKD experiment on TRAFD1 to gainmore
insights into the biological function of this gene and to validate
the TRAFD1 trans-mediated genes in a functional assay. We
evaluated the transcriptional changes of knocking down TRAFD1
in the monocyte-like cell line THP-1 under resting conditions
(unstimulated) or in the presence of LPS, a known inducer of
the NFκB pathway (Dorrington and Fraser, 2019). We selected
this cell line considering the role of monocytes in modulating
the epithelial barrier function and cytokine secretion in a CeD-
specific context (Delbue et al., 2019), as well as for the technical
ability to alter the expression of TRAFD1 using siRNA and the
quick response of monocytes to LPS (Sharif et al., 2007).
After siRNA treatment, we observed no significant differences
in cell viability or proliferation among the controls (WT and
SCR) and the KD treatment (Supplementary Figures 3A,B).
However, as expected for the KD cell line, we noted a significant
reduction in the expression of TRAFD1 compared to the
controls in both WB and qPCR analyses (Figures 4A–C). KD
of TRAFD1 was also confirmed in the RNA-seq data, with
TRAFD1 expression levels reduced by 41% in unstimulated KD
cells compared to unstimulated SCR cells (adjusted p = 0.004)
and by 34% in LPS-stimulated KD cells compared to LPS-
stimulated SCR cells (not significant) (Supplementary Table 11).
The reduced KD effect upon LPS stimulation is consistent with
our expectation that TRAFD1 acts as a negative regulator of the
NFκB pathway, which is activated by several stimuli, including
LPS (Dorrington and Fraser, 2019). Therefore, we considered
the KD as successful, and neither the transfection method nor a
reduced expression of TRAFD1 had a toxic effect (Figures 4A–C,
Supplementary Figure 3).
Next, we tested if the 41 TRAFD1 trans-mediated genes were
more differentially expressed than expected after LPS stimulation
(Figure 4D). To disentangle differential expression from the co-
expression inherently present in a gene expression dataset, we
devised a permutation scheme that compared the control (WT
vs. SCR) observations with the KD (SCR vs. KD) observations
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FIGURE 3 | Trans genes action and function. (A) Circle genomic plot depicting the location of the 41 genes trans-mediated by TRAFD1. The three genes also
prioritized by our cis-eQTL analysis are named (red). (B) Results of the REACTOME gene set enrichment analysis of TRAFD1-mediated genes. Color code denotes
the significance (-log 10 adjusted p-value) of each biological pathway.
(see Methods). This scheme takes into account the co-expression
of a gene set, as this co-expression is present in both the control
and the experimental observation. After performing 1,000,000
permutations of 42 genes (41 trans-mediated genes andTRAFD1)
in the LPS-stimulated comparison, the median test statistic in
the control observations was observed 52.8 times more often
than in the KD observations (0.264% for WT-SCR vs. 0.005%
for SCR-KD, Supplementary Figure 4). This indicates that the
41 trans-mediated genes and TRAFD1 as a set are 54 times
more differentially expressed than expected. We did not find
increased differential expression of the same gene set in the
unstimulated condition (1.120% for WT-SCR vs. 0.307% for
SCR-KD; Figure 4D, Supplementary Figure 4), indicating that
TRAFD1mainly regulates genes in an LPS-stimulated state.
RNA Sequencing in Celiac
Disease-Relevant Cell Types Identifies
Tissue-Specific Biological Function
To complement our REACTOME gene set enrichment analysis
and dig deeper into the biological processes and cell types in
which the 118 prioritized genes may act, we analyzed their
expression profiles in available RNA-seq datasets from disease-
relevant cell types including (1) small intestinal biopsies of active
CeD patients and healthy controls; (2) IE-CTLs stimulated with
disease-relevant cytokines IL-21, IL-15, and IFNβ; and (3) gluten-
specific CD4+ T cells (gsCD4+ T cells) stimulated with anti-
CD3–anti-CD28, which mimics the disease-specific response
to gluten peptides (Supplementary Figure 5) (DEGs for each
dataset are available in Supplementary Table 12).
We observed that the genes contained in the cluster not
showing enrichment for particular biological functions and
those contained in the cluster enriched for IFNγ signaling
(green and red, Figure 2) identified in the analysis described
in Co-Regulation Patterns of cis-Expression Quantitative Trait
Loci-Prioritized Loci Reveals Four Functional Clusters are most
expressed in CeD patient-derived small intestinal biopsies
(Supplementary Figure 5A). Similarly, some TRAFD1 trans-
mediated genes such as STAT1, CXCL10, and TAP1, which are
essential for IFN response (Kim H. S. et al., 2015), chemotaxis
(Majumder et al., 2012), and antigen processing (Seyffer and
Tampé, 2015), respectively (Supplementary Figure 5B), were
found to be upregulated mainly in the biopsy samples derived
from CeD patients.
Genes contained in these two clusters were also highly
expressed in stimulated IE-CTLs, which is in line with the
IFNγ pathway enrichment observed (Figure 2). IFNγ is mainly
produced by gsCD4+ T cells and IE-CTLs and is known to
disrupt the integrity of the intestinal epithelial cells in CeD-
associated villous atrophy (Nilsen et al., 1995; Wapenaar et al.,
2004; Abadie et al., 2012). Moreover, most TRAFD1 trans-
mediated genes exhibit an increase in expression in response to
IFNγ in intestinal epithelial cells (Caco-2) or IFNβ in IE-CTLs
(Supplementary Figure 5B).
The genes in the co-regulation clusters enriched for TCR
signaling and chemokine and cytokine signaling (cyan and pink
clusters, Figure 2) were instead highly expressed in gsCD4+T
cells, especially after stimulation with anti-CD3/anti-CD28,
indicating that these prioritized genes may be biologically
relevant in the immediate T cell receptor response to gluten
ingestion (Supplementary Figure 5A). In contrast, antiCD3–
antiCD28 stimulation in gsCD4+T cells resulted in both
upregulation and downregulation of theTRAFD1 trans-mediated
genes, implying that TRAFD1 trans-mediated genes respond
more strongly to IFN signaling (IFNγ or IFNβ) than to TCR
activation by anti-CD3/anti-CD28 (Supplementary Figure 5B).
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FIGURE 4 | In vitro knockdown of TRAFD1 validates trans-mediation network.
THP-1 cell line based knockdown of TRAFD1 (KD) compared to non-specific
siRNA (SCR) and untransfected cells (WT) (A) Western blot based protein
levels of TRAFD1 compared to the B actin control. p ≤ 0.0001 (****). (B) qPCR
RNA levels and (C) RNA-seq levels of TRAFD1 expression. (D) Comparative
differential expression experiment of TRAFD1, comparing the 41
trans-mediated genes and TRAFD1 differential expression in the WT vs. SCR
to the SRC vs. KD in the LPS stimulated condition. The WT vs. SCR is 52.8
times less differentially expressed as the SCR vs. KD, indicating that TRAFD1
KD affects these 41 genes in trans.
Taken together, the gene expression patterns of the 118
prioritized genes, when combined with information from
our literature search (Figure 1B, Supplementary Tables 4, 12),
suggest that these genes may control general biological processes
(e.g., apoptosis, gene regulation, and cytoskeleton remodeling)
as well as specific immune functions (e.g., cell adhesion,
cell differentiation, and TCR signaling) in diverse cell types
(e.g., T cells, neutrophils, B cells, monocytes, epithelial cells)
(Supplementary Figure 5, Supplementary Table 12). The non-
HLA genetic loci associated with CeD thus seem to affect a
complex network of cells and biological processes. Of note, when
we analyzed the enrichment of the 41 TRAFD1 trans-mediated
genes in significantly DEGs in CeD relevant cell types, we found
that the enrichment was strongest in IE-CTLs and epithelial cells
upon IFN signaling (Supplementary Table 12), suggesting that
TRAFD1 and TRAFD1-mediated genes modulate IFN signaling
possibly via regulation of NFκB in the context of the CeD
inflammatory environment.
DISCUSSION
In the present study, we aimed to identify CeD candidate
genes using four in silico methods (MR-IVW, COLOC, LD
overlap, and DEPICT) and whole blood transcriptomics data
from a population-based cohort. While previous studies have
used at least one of these methods (Trynka et al., 2011; Withoff
et al., 2016; Fernandez-Jimenez and Bilbao, 2019; Ricaño-
Ponce et al., 2020), to our knowledge, this is the first effort
that integrates these four different statistical approaches. This
systematic prioritization approach resulted in 118 prioritized
likely causal genes, including 26 that are direct targets of an
approved drug or of drugs under development for other complex
diseases, including autoimmune diseases. The co-expression
pattern within a large RNA-seq dataset from blood (Deelen
et al., 2019) suggests that these genes are involved in cytokine
signaling in innate and adaptive cells as well as in T-cell receptor
activation pathways.
We also ran a trans-mediation analysis at CeD loci by
incorporating trans-eQTLs; these have mostly been ignored
by other prioritization studies that have thus missed long-
distance co-regulation interactions (Brynedal et al., 2017). With
this analysis, we identified one of the 118 prioritized genes,
TRAFD1, to be trans-regulator of 41 genes, a set of genes showing
a strong enrichment in IFNγ signaling and MHC I antigen
processing/presentation pathways, which are pivotal for the
disease pathogenesis. Using siRNA experiments, we confirmed a
significant perturbation of these 41 genes after blocking TRAFD1
expression, a signal that was not seen instead for the 502 genes
identified by Võsa et al. (2018), trans-regulated by one of the
TRAFD1 eQTL variants (data not shown). This may indicate that
our mediation analysis restricted the gene set to reflect a more
defined role of TRAFD1 in CeD.
TRAFD1 has not been related to CeD previously (Withoff
et al., 2016; Ricaño-Ponce et al., 2020). This gene is thought to be
a regulator of the NFκB signaling pathway (Sanada et al., 2008),
a pathway that is abnormally activated in the intestinal mucosa
of CeD patients (Fernandez-jimenez et al., 2014). Our results
suggest for the first time a role of TRAFD1 in signaling response
to potentially both type I and type II IFNs. IFNγ-mediated type
II IFN and IFNβ-mediated type I IFN activation both involve
activation of the NFκB pathway (Deb et al., 2001; Pfeffer, 2011;
Thapa et al., 2011; Meyerovich et al., 2016; Mitchell et al., 2019),
and TRAFD1 and TRAFD1-mediated genes respond strongly to
both IFNs in IE-CTLs and intestinal epithelial cells. Interestingly,
the IFNG or IFNB loci are not associated with CeD directly. We
therefore hypothesize that TRAFD1 provides a genetic link to the
IFN response in CeD patients.
IE-CTLs, which are the effector cells in CeD, have not thus
far been directly genetically associated with the disease. However,
given the activation of at least half of the 41 trans-mediated genes
in IE-CTLs upon IFN stimulation, we propose that the IE-CTLs
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may also be genetically linked to the disease through the action
of TRAFD1.
We acknowledge the limitations of our study that could
have restricted our findings. For example, a drawback is the
limited genome coverage of the CeD summary statistics used
in this study. Immunochip only measures genotypes in regions
known to be associated with immune function. Therefore, our
current interpretation of CeD loci is biased toward immune-
related mechanisms. Only when comprehensive whole-genome
CeD association analyses will become available can this bias
be removed. Another constraint is the lack of a gold standard
method to select relevant genes at an associated locus. In our
combined gene prioritization approach, we observed that the
four different statistical methods applied to our data identified
unique and jointly prioritized genes. While we believe that the
genes prioritized in this study represent robustly prioritized genes
for CeD, it is difficult to prove that all the prioritized genes are
truly causal based on statistical methodology alone. For instance,
in the MR-IVW method for causality, it is impossible to rule out
pleiotropic effects, even though we do find that our estimates
are not overly heterogeneous (Burgess and Thompson, 2015).
Moreover, for many genes, there were not enough eQTLs to apply
this causality test. Functional validation of these genes in disease
context is needed to rule out false positives. In this study, we used
eQTLs derived from whole blood, which is a relevant tissue in
CeD, but it will not capture all causal genes across different tissues
(Ongen et al., 2017). We have attempted to mitigate this bias by
including DEPICT in our analyses, which uses co-expression data
from many tissues regardless of eQTLs. Tissue limitations also
apply to the translation of the prioritized genes to the differential
expression experiments performed in the disease-relevant cell
types. Genes found in blood do not directly translate to other
cell types.
In conclusion, this study provides a framework for predicting
candidate genes and their function using a systematic in silico
approach that could be extended to other complex diseases.
Using this approach, we not only confirmed previous association
between adaptive cells (gsCD4+ T cells and B cells) and
CeD but also unveil a link between specific genes that may
contribute to the disease via innate immune cells, epithelial cells,
and IE-CTLs. Finally, we identified a novel master regulator,
TRAFD1, influencing a set of genes enriched for two major
pathways of immune activation, IFNγ signaling and antigen
processing, which could thus be a potential target for therapeutic
interventions in CeD.
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Supplementary Figure 1 | Cis-eQTL prioritized candidate genes in CeD loci, and
workflow of this study (A) The workflow of this study. We have combined the CeD
summary statistics with the BIOS cohort and multi tissue expression data to
identify a list of 118 prioritized genes likely causal for CeD pathophysiology. We
further performed a trans-mediation analysis to identify the downstream targets of
these genes. We performed functional follow-up of the strongest trans-mediating
genes using an siRNA screen in the THP1 cell-line. Finally, we overlay disease
relevant cell types with the prioritized and trans-mediated genes to elucidate their
action in disease-relevant cell types and conditions. (B) A CeD GWAS association
curve at a hypothetical GWAS locus X and the eQTL association at a potential
candidate gene A. In both association plots, each dot represents a SNP plotted
against the genomic position (X axis) and the strength of association (Y axis). In
the GWAS association curve, the top SNP is marked in red, while other SNPs
above the significance threshold (dashed line) are colored according to their LD
with the top SNP. In the eQTL association curve, independent eQTLs are marked
in red. (C) A conceptual depiction of the four statistical methods applied to link a
disease locus to an eQTL locus.
Supplementary Figure 2 | Trans mediation analysis workflow, and trans
mediation in the TRAFD1 locus on chromosome 12 (A) Workflow illustrating the
main steps to identify trans-eQTL genes mediated by our cis-prioritized genes.
First, we identified trans-eQTLs and trans genes that have a significant association
(p < 5 × 10−8) in our prioritized regions. Then, for every cis prioritized gene in the
CeD-associated region, a mediation analysis was performed to determine if the cis
gene expression explains the trans-eQTL effect. (B) Three boxes with the eQTL
association curves of TRAFD1, SERPING1, and SERPING1 after mediation with
TRAFD1. (C) Scatter plot indicating the absolute Z difference between
unmediated and mediated trans associations upon mediation (y axis) by all
mediating cis genes in the TRAFD1 region shown on the x axis as well as when
correcting TRAFD1 expression for the expression of SH2B3 (‘TRAFD1 – SH2B3’).
Supplementary Figure 3 | TRAFD1 knockdown validation. Cell viability (A) and
proliferation (B) of THP-1 cells that were left untransfected (WT) or transfected
with non-targeting siRNA (SCR) or siRNA targeting TRAFD1 (KD) for 72 h. (C) The
differential expression analysis approach.
Supplementary Figure 4 | DEGs upon TRAFD1 knockdown (A) Heatmap
showing the pattern of gene expression of TRAFD1 and of the 41 genes it
mediates, scaled by row (see details in Methods). Expression is shown in different
treatments and stimulations as indicated by colored bars on top of the heatmap.
(B–D) Comparison of the differential expression of 42 genes found in the trans
mediation analysis of TRAFD1 (41 trans-mediated genes and TRAFD1) with the
differential expression of 42 other randomly chosen genes. The histograms (blue)
show the distribution of the median absolute T statistic of DEseq of 42 randomly
chosen genes, when 1,000,000 sets of genes are randomly chosen, compared to
the observed value for the 42 genes that are from the trans-mediation analysis
(red horizontal line). We compare the results of the control experiment (WT-SCR) in
(B,D) with the results of the knockdown experiment (SCR-KD) in (C,E). The fold
differences between the control experiments and the knockdown experiments
show how much more than expected the 42 genes are differentially expressed in
the knockdown compared to the control.
Supplementary Figure 5 | Differential expression of prioritized and
trans-mediated genes in disease relevant cell types. (A) Heatmap depicting the
scaled expression of the 118 prioritized genes belonging to the four clusters
identified in Figure 2A in three available RNA-seq datasets: intestinal biopsies
from controls (CTR, n = 5 samples) or CeD patients (CeD, n = 6 samples); CD8+
TCRαβ intraepithelial cytotoxic lymphocytes (IE-CTLs) unstimulated or treated with
IL-21, IL-15, or IFNβ for 3 h (n = 8 samples per condition) and gsCD4+ T cells
unstimulated or treated with anti-CD3 and anti-CD28 (aCD3) for 3 h (n = 22
samples per condition). Clustering was performed using the “average” method in
hclust(). (B) Unscaled heatmaps depicting the expression of 41 TRAFD1
trans-mediated genes and TRAFD1 in RNA-seq datasets from the cell types listed
above as well as Caco-2 cells untreated or stimulated with IFNγ for 3 h (n = 8
samples per condition). Red indicates that a gene is differentially expressed (DE),
blue indicates that a gene is not differentially expressed (non-DE) (FDR < 0.01 and
|log2(RPKM)>1|). Gray (none or unstimulated), pink (IFNγ), green (IFNβ), and
yellow (antiCD3/antiCD28) colors indicate the type of stimulation (treatment).
Supplementary Table 1 | Prioritization of genes likely causal for celiac disease
(CeD). This table contains all the genes in the prioritized CeD regions and their
evidence for being causal to CeD. One gene per row is shown. Columns (in order):
the human build 37 coordinates of the CeD region in which the gene is located
(region); the gene name according to the ENSEMBL GENES 96 database (human
build 37) (gene_name); the ENSEMBL gene identifier (ensembl_id); the most
likely effect direction (determined as described in Methods)
(most_likely_direction); number of independent eQTL variants found for the
gene (n_eqtl_effects); the effect size (MR_ivw_effect) and p-value
(MR_ivw_p_value) of the MR-IVW test; the summary of LD overlap
(ld_overlap_summary), with either the top eQTL variant (“top_snp”) or an
independent eQTL variant (“cojo_snp”) with the r2 linkage disequilibrium between
the eQTL SNP and the CeD top variant; the coloc posterior probability of causal
variants being shared (coloc_h4); if the gene passes DEPICTs own false discovery
thresholds (depict_fdr_pass); and the lines of evidence that are significant
compared to the lines of evidence that are available for a gene
(lines_of_evidence). Bold fields in any of the columns indicate that the
prioritization method is significant according to our thresholds.
Supplementary Table 2 | Sensitivity analyses for genes selected by the IVW-MR
method. In this table, genes with a significant MR-IVW effect are tested for
heterogeneity using the Q-test statistic and the MR-weighted median results as
sensitivity analysis of all significant MR results. Each row contains the following
information: the human build 37 coordinates of the CeD region in which the gene
is located (region); the gene name according to the ENSEMBL GENES 96
database (human build 37) (gene_name); the ENSEMBL gene identifier
(ensembl_id); the most likely direction of the effect (determined as described in
Methods) (most_likely_direction); the number of independent eQTL variants
found (n_eqtl_effects); the effect size (MR_ivw_effect) and p-value
(MR_ivw_p_value) of the MR-IVW test; the heterogeneity p-value of the MR-IVW
test using Cochran’s Q statistic (MR_heterogeneity_p_value); the weighted
median effect estimate (MR_WM_beta) and its associated p-value (MR_WM_p);
the MR effect estimate after removal of potential outliers (MR_Q_beta); its
associated p-value (MR_Q_p); the remaining variants after outlier removal
(MR_Q_ivs) and the heterogeneity estimate (MR_Q_heterogeneity).
Supplementary Table 3 | Druggability information for prioritized genes. This table
contains all the prioritized cis genes in the CeD regions that are existing drug
targets according to two different databases (DrugBank v5.1.4, and Finan et al.,
2017). One gene per row is shown. Columns indicate (in order): the human build
37 coordinates of the CeD region in which the gene is located (region); the gene
name according to the ENSEMBL GENES 96 database (human build 37)
(gene_name); the ENSEMBL gene identifier (ensembl_id); the most likely effect
direction (determined as described in Methods) (most_likely_direction); the
number of independent eQTL variants found for the gene (n_eqtl_effects); the
effect size (MR_ivw_effect) and p-value (MR_ivw_p_value) of the MR-IVW test;
the summary of LD overlap (ld_overlap_summary) with either the top eQTL
variant (“top_snp”) or an independent eQTL variant (“cojo_snp”) with the r2 linkage
disequilibrium between the eQTL SNP and the CeD top variant; the coloc
posterior probability of causal variants being shared (coloc_h4); if the gene
passes DEPICT’s own false discovery thresholds (depict_fdr_pass); the lines of
evidence that are significant compared to the lines of evidence that are available
for a gene (lines_of_evidence); the druggability tier based on Finan et al. (2017),
with lower tiers making it more likely that the gene is druggable (Finan et al., 2017),
(druggable_tier), and if the gene is a drug bank drug target
(drug_bank_drug_target). Bold fields in any of the columns indicate that the
prioritization method is significant according to our thresholds.
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Supplementary Table 4 | Functions attributable to the prioritized genes,
according to our literature review (see Methods and Figure 1B). Columns
describe (in order): gene name (gene_name); ensemble ID (ensembl_id); the
change that leads to increased CeD risk, i.e., increased expression (+), decreased
expression (–), or undefined (?) (direction); attributable function based in literature
(potential_function); and literature or web-based sources (source_1 and
source_2). Web-based sources include Gene cards (https://www.genecards.
org/) and Genenetwork (https://www.genenetwork.nl/).
Supplementary Table 5 | Cluster assignments for the prioritized genes. The 118
prioritized genes were assigned to a cluster based on a guilt-by-association
co-regulation approach to find shared biological mechanisms. For each gene that
was prioritized (ensembl_id and gene_name), a cluster membership is given
(cluster_membership).
Supplementary Table 6 | Significant REACTOME 2016 enrichment of cis
prioritized genes in each co-regulation cluster. Results from the enrichr API using
the gene clusters of Supplementary Table 5 as query. Columns indicate: the
enrichment background (background); the enrichment term in the background
(term_name); the non-corrected p-value of enrichment for this term (p_value)
and Z score (Z_score); enrichr combined score (combined_score); cis-prioritized
genes found in each the term (overlapping_genes) and the multiple testing
corrected p-value (adjusted_p_value). Each tab of the excel file contain the gene
set enrichment for each cluster as defined in Supplementary Table 5.
Supplementary Table 7 | All the significant trans-mediated genes from our cis
prioritization. Each row contains a cis–trans gene pair described with both the
ensembl id and hgnc gene name (cis_ensembl_id), (cis_gene_name),
(trans_ensembl_id), and (trans_gene_name). Mediation effect and significance
are shown using the Z score of the unmediated vs. the mediated estimate (using
the original unmediated standard error) (z_score_difference) and the mediation
p-value of the test defined by Friedman and Schatzkin (mediation_p).
Supplementary Table 8 | Cell type mediation analysis. We calculated to what
extent cell types counted in the BIOS cohort affect the most highly associated
TRAFD1 eQTL variant. Columns show (in order): the specific cell type
measurements or mediator (mediator); the effect size after mediation by the cell
type (mediated_beta); the original effect size (unmediated_beta); difference in
effect sizes between mediated and unmediated (beta_difference); the standard
error mediation effect size (se); the t-statistic of the beta differences (t_statistic); a
p-value of the Friedman and Schatzkin test statistic (p_value); the Pearson
correlation coefficient between TRAFD1 and the cell type proportion (correlation);
and the number of observations in the BIOS cohort (n_observations). If a
mediator has a “_Perc” suffix, the cell type counts were converted into ratios. Cell
type abbreviations: Baso, Basophil count; EOS, eosinophil count; HCT,
haematocrit; HGB, hemoglobin; LUC, large unstained cell count; Lymph,
lymphocyte count; MCH, mean corpuscular hemoglobin; MCHC, mean
corpuscular hemoglobin concentration; MCV, mean corpuscular volume; Mono,
Monocyte count; MPV, mean platelet volume; Neut, Neutrophil count; PLT,
platelets count; RBC, red blood cell count; RDW, red blood cell distribution width;
WBC, white blood cell count.
Supplementary Table 9 | Mediation results when correcting TRAFD1 expression
for the nearby SH2B3 expression. Columns are: the ENSEMBL id (ensemble_id);
the hgnc gene name (gene_name); and the mediation Z score difference
(Z_score_difference), p-value (p_value) and Pearson correlation (correlation)
between the trans-eQTL top variant and the residual of TRAFD1 expression, after
correction for SH2B3 expression.
Supplementary Table 10 | Significant REACTOME 2016 enrichment of
TRAFD1-mediated genes. Results from the enrichr API using the mediated
TRAFD1 trans genes as query. Columns indicate: the enrichment background
(background); the enrichment term in the background (term_name); the
non-corrected p-value of enrichment for this term (p_value) and Z score
(Z_score); enrichr combined score (combined_score); cis-prioritized genes
found in each the term (overlapping_genes) and the multiple-testing-corrected
p-value (adjusted_p_value).
Supplementary Table 11 | Differential expression results of the THP-1
experiments. This table shows differential expression analysis of the THP-1 cells
with 3 h LPS treatment (LPS) or without LPS (Unstim) in wild type (WT), scrambled
control siRNA (SCR) or TRAFD1 knock down conditions (KD). All conditions and
treatments were performed in triplicate. Complete DESEQ2 results are shown for
each possible comparison in each tab. For each gene the columns show: the
ensembl id per gene (ensembl_id); the mean corrected expression of the gene
(baseMean); the log2 fold change of the comparison (log2FoldChange); the
standard error of this log2 fold change (lfcSE); a t-statistic of the log2foldchange
(stat); the p-value (pvalue); and the multiple testing adjusted p-value (padj). The
direction of the effect is always toward the second term in the tab name: if a log2
fold change is positive and the tab name is, for example,
“WT_LPS_vs_SCR_LPS,” then the expression of the gene is increased in the
SCR_LPS samples compared to the WT_LPS samples.
Supplementary Table 12 | Results of DE analyses from all cell-type- and
context-specific data available for this study (datasets). This table lists all results
for the DE analyses (Significant DE genes are defined as padj < 0.05 and log2 fold
change > |1|) and a summary report of the overlap with TRAFD1 trans-mediated
genes (overlap with trans genes+TRAFD1) and relative enrichment. The DE
gene lists (padj < 0.05 and log2 fold change > |1|) for each dataset are given in
individual sheets. In the sheet “enrichment,” columns upregulated and
downregulated indicate if the trans-mediated genes are up- or downregulated
under stimulated conditions compared to control conditions in each dataset.
Enrichment of all the trans-mediated genes in the DE genes was determined using
a Fisher’s exact test and the enrichment p-value is shown in the column
enrichment p-val.
REFERENCES
Abadie, V., Discepolo, V., and Jabri, B. (2012). Intraepithelial lymphocytes
in celiac disease immunopathology. Semin. Immunopathol. 34, 551–556.
doi: 10.1007/s00281-012-0316-x
Anders, S., and Huber, W. (2010). Differential expression analysis for
sequence count data. Genome Biol. 11:R106. doi: 10.1186/gb-2010-11-
10-r106
Astle, W. J., Elding, H., Jiang, T., Allen, D., Ruklisa, D., Mann, A. L., et al. (2016).
The allelic landscape of human blood cell trait variation and links to common
complex disease. Cell 167, 1415–1429.e19. doi: 10.1016/j.cell.2016.10.042
Auton, A., Abecasis, G. R., Altshuler, D. M., Durbin, R. M., Bentley, D. R.,
Chakravarti, A., et al. (2015). A global reference for human genetic variation.
Nature 526, 68–74. doi: 10.1038/nature15393
Baldassari, L. E., and Rose, J. W. (2017). Daclizumab: development, clinical trials,
and practical aspects of use inmultiple sclerosis.Neurotherapeutics 14, 842–858.
doi: 10.1007/s13311-017-0553-8
Bevan, S., Popat, S., Braegger, C. P., Busch, A., O’Donoghue, D., Falth-Magnusson,
K., et al. (1999). Contribution of the MHC region to the familial risk of coeliac
disease. J. Med. Genet. 36, 687–690.
Bowden, J., Hemani, G., and Davey Smith, G. (2018). Invited commentary:
detecting individual and global horizontal pleiotropy in mendelian
randomization-a job for the humble heterogeneity statistic? Am. J. Epidemiol.
187, 2681–2685. doi: 10.1093/aje/kwy185
Brynedal, B., Choi, J. M., Raj, T., Bjornson, R., Stranger, B. E., Neale, B. M., et al.
(2017). Large-scale trans-eQTLs affect hundreds of transcripts and mediate
patterns of transcriptional co-regulation. Am. J. Hum. Genet. 100, 581–591.
doi: 10.1016/j.ajhg.2017.02.004
Burgess, S., Butterworth, A., and Thompson, S. G. (2013). Mendelian
randomization analysis with multiple genetic variants using summarized data.
Genet. Epidemiol. 37, 658–665. doi: 10.1002/gepi.21758
Burgess, S., and Thompson, S. G. (2017). Interpreting findings from mendelian
randomization using the MR-egger method. Eur. J. Epidemiol. 32, 377–389.
doi: 10.1007/s10654-017-0255-x
Frontiers in Genetics | www.frontiersin.org 14 January 2021 | Volume 11 | Article 562434
van der Graaf et al. TRAFD1 Is Trans-Regulator in CeD
Burgess, S., and Thompson, S. G. (2015). Mendelian Randomization: Methods for
Using Genetic Variants in Causal Estimation. Cambridge: CRC Press, 1–207.
doi: 10.1201/b18084
Chang, C. C., Chow, C. C., Tellier, L. C. A. M., Vattikuti, S., Purcell, S. M., and
Lee, J. J. (2015). Second-generation PLINK: rising to the challenge of larger and
richer datasets. Gigascience 4:7. doi: 10.1186/s13742-015-0047-8
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., et al.
(2013). Enrichr: interactive and collaborative HTML5 gene list enrichment
analysis tool. BMC Bioinformatics 14:128. doi: 10.1186/1471-2105-1
4-128
Chiu, Y. G., and Ritchlin, C. T. (2017). Denosumab: targeting the RANKL
pathway to treat rheumatoid arthritis. Expert Opin. Biol. Ther. 17, 119–128.
doi: 10.1080/14712598.2017.1263614
Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A. E., Kwong, A., et al. (2016).
Next-generation genotype imputation service and methods. Nat. Genet. 48,
1284–1287. doi: 10.1038/ng.3656
Deb, A., Haque, S. J., Mogensen, T., Silverman, R. H., and Williams, B. R. G.
(2001). RNA-dependent protein kinase PKR is required for activation of NF-
κB by IFN-γ in a STAT1-independent pathway. J. Immunol. 166, 6170–6180.
doi: 10.4049/jimmunol.166.10.6170
Deelen, J., van den Akker, E. B., Trompet, S., van Heemst, D., Mooijaart, S. P.,
Slagboom, P. E., et al. (2016). Employing biomarkers of healthy ageing for
leveraging genetic studies into human longevity. Exp. Gerontol. 82, 166–174.
doi: 10.1016/j.exger.2016.06.013
Deelen, P., van Dam, S., Herkert, J. C., Karjalainen, J. M., Brugge, H., Abbott, K.M.,
et al. (2019). Improving the diagnostic yield of exome- sequencing by predicting
gene–phenotype associations using large-scale gene expression analysis. Nat.
Commun. 10:2837. doi: 10.1038/s41467-019-10649-4
Delbue, D., Cardoso-Silva, D., Branchi, F., Itzlinger, A., Letizia, M., Siegmund,
B., et al. (2019). Celiac disease monocytes induce a barrier defect in intestinal
epithelial cells. Int. J. Mol. Sci. 20:5597. doi: 10.3390/ijms20225597
Dorrington, M. G., and Fraser, I. D. C. (2019). NF-κB signaling in macrophages,
dynamics, crosstalk, and signal integration. Front. Immunol. 10:705.
doi: 10.3389/fimmu.2019.00705
Dubois, P. C. A., Trynka, G., Franke, L., Hunt, K. A., Romanos, J., Curtotti, A.,
et al. (2010). Multiple common variants for celiac disease influencing immune
gene expression. Nat. Genet. 42, 295–302. doi: 10.1038/ng.543
Esche, C., Stellato, C., and Beck, L. A. (2005). Chemokines: key players
in innate and adaptive immunity. J. Invest. Dermatol. 125, 615–628.
doi: 10.1111/j.0022-202X.2005.23841.x
Fernandez-Jimenez, N., and Bilbao, J. R. (2019). Mendelian randomization
analysis of celiac GWAS reveals a blood expression signature with diagnostic
potential in absence of gluten consumption. Hum. Mol. Genet. 28, 3037–3042.
doi: 10.1093/hmg/ddz113
Fernandez-jimenez, N., Castellanos-rubio, A., Plaza-izurieta, L., Irastorza,
I., Elcoroaristizabal, X., Jauregi-miguel, A., et al. (2014). Coregulation
and modulation of NFκB-related genes in celiac disease: uncovered
aspects of gut mucosal inflammation. Hum. Mol. Genet. 23, 1298–1310.
doi: 10.1093/hmg/ddt520
Finan, C., Gaulton, A., Kruger, F. A., Lumbers, R. T., Shah, T., Engmann, J.,
et al. (2017). The druggable genome and support for target identification
and validation in drug development. Sci. Transl. Med. 9:eaag1166.
doi: 10.1126/scitranslmed.aag1166
Freedman, L. S., and Schatzkin, A. (1992). Sample size for studying
intermediate endpoints within intervention trials or observational studies.
Am. J. Epidemiol. 136, 1148–1159. doi: 10.1093/oxfordjournals.aje.a11
6581
Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D.,
Wallace, C., et al. (2014). Bayesian test for colocalisation between pairs of
genetic association studies using summary statistics. PLoS Genet. 10:e1004383.
doi: 10.1371/journal.pgen.1004383
Graaf, A., van der Zorro, M., Claringbould, A., Vosa, U., Aguirre-Gamboa, R.,
Li, C., et al. (2020). Systematic prioritization of candidate genes in disease
loci identifies TRAFD1 as a master regulator of IFNγ signalling in celiac
disease. bioRxiv [Preprint]. doi: 10.1101/2020.03.04.973487
Grenningloh, R., Bok, Y. K., and Ho, I. C. (2005). Ets-1, a functional cofactor of
T-bet, is essential for Th1 inflammatory responses. J. Exp. Med. 201, 615–626.
doi: 10.1084/jem.20041330
Hofman, A., Brusselle, G. G. O., Murad, S. D., van Duijn, C. M., Franco, O.
H., Goedegebure, A., et al. (2015). The rotterdam study: 2016 objectives
and design update. Eur. J. Epidemiol. 30, 661–708. doi: 10.1007/s10654-015-
0082-x
Huisman, M. H. B., De Jong, S. W., Van Doormaal, P. T. C., Weinreich,
S. S., Schelhaas, H. J., Van Der Kooi, A. J., et al. (2011). Population
based epidemiology of amyotrophic lateral sclerosis using capture-
recapture methodology. J. Neurol. Neurosurg. Psychiatr. 82, 1165–1170.
doi: 10.1136/jnnp.2011.244939
Jabri, B., De Serre, N. P. M., Cellier, C., Evans, K., Gache, C., Carvalho, C., et al.
(2000). Selective expansion of intraepithelial lymphocytes expressing the HLA-
E- specific natural killer receptor CD94 in celiac disease. Gastroenterology 118,
867–879. doi: 10.1016/S0016-5085(00)70173-9
Jonkers, I. H., and Wijmenga, C. (2017). Context-specific effects of genetic
variants associated with autoimmune disease. Hum. Mol. Genet. 26, R185–
R192. doi: 10.1093/hmg/ddx254
Kim, D., Langmead, B., and Salzberg, S. L. (2015). HISAT: a fast spliced aligner with
lowmemory requirements.Nat.Methods 12, 357–360. doi: 10.1038/nmeth.3317
Kim, H. S., Kim, D. C., Kim, H. M., Kwon, H. J., Kwon, S. J., Kang, S. J.,
et al. (2015). STAT1 deficiency redirects IFN signalling toward suppression
of TLR response through a feedback activation of STAT3. Sci. Rep. 5:13414.
doi: 10.1038/srep13414
Kuja-Halkola, R., Lebwohl, B., Halfvarson, J., Wijmenga, C., Magnusson, P. K.
E., and Ludvigsson, J. F. (2016). Heritability of non-HLA genetics in coeliac
disease: a population-based study in 107 000 twins. Gut 65, 1793–1798.
doi: 10.1136/gutjnl-2016-311713
Kumar, V., Gutierrez-Achury, J., Kanduri, K., Almeida, R., Hrdlickova, B.,
Zhernakova, D. V., et al. (2015). Systematic annotation of celiac disease
loci refines pathological pathways and suggests a genetic explanation
for increased interferon-gamma levels. Hum. Mol. Genet. 24, 397–409.
doi: 10.1093/hmg/ddu453
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al.
(2009). The sequence alignment/map format and SAMtools. Bioinformatics 25,
2078–2079. doi: 10.1093/bioinformatics/btp352
Liao, Y., Smyth, G. K., and Shi, W. (2019). The R package rsubread is easier, faster,
cheaper and better for alignment and quantification of RNA sequencing reads.
Nucleic Acids Res. 47:e47. doi: 10.1093/nar/gkz114
Lin, B. D., Willemsen, G., Abdellaoui, A., Bartels, M., Ehli, E. A., Davies, G. E., et al.
(2016). The genetic overlap between hair and eye color. Twin Res. Hum. Genet.
19, 595–599. doi: 10.1017/thg.2016.85
Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:550.
doi: 10.1186/s13059-014-0550-8
Lu, L. L., Suscovich, T. J., Fortune, S. M., and Alter, G. (2018). Beyond binding:
antibody effector functions in infectious diseases.Nat. Rev. Immunol. 18, 46–61.
doi: 10.1038/nri.2017.106
Mahnke, J., Schumacher, V., Ahrens, S., Käding, N., Feldhoff, L. M., Huber, M.,
et al. (2016). Interferon regulatory factor 4 controls T H1 cell effector function
and metabolism. Sci. Rep. 6:35521. doi: 10.1038/srep35521
Majumder, S., Bhattacharjee, S., Paul Chowdhury, B., and Majumdar, S. (2012).
CXCL10 is critical for the generation of protective CD8T cell response induced
by antigen pulsed CpG-ODN activated dendritic cells. PLoS ONE 7:e48727.
doi: 10.1371/journal.pone.0048727
Meunier, E., and Broz, P. (2016). Interferon-inducible GTPases in cell autonomous
and innate immunity. Cell. Microbiol. 18, 168–180. doi: 10.1111/cmi.12546
Meyerovich, K., Fukaya, M., Terra, L. F., Ortis, F., Eizirik, D. L., and Cardozo,
A. K. (2016). The non-canonical NF-κB pathway is induced by cytokines
in pancreatic beta cells and contributes to cell death and proinflammatory
responses in vitro. Diabetologia 59, 512–521. doi: 10.1007/s00125-015-
3817-z
Mitchell, S., Mercado, E. L., Adelaja, A., Ho, J. Q., Cheng, Q. J., Ghosh, G., et al.
(2019). An NFκB activity calculator to delineate signaling crosstalk: type I and
II interferons enhanceNFκB via distinctmechanisms. Front. Immunol. 10:1425.
doi: 10.3389/fimmu.2019.01425
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